Neonatal Jaundice: Perception and Care Seeking Behaviours among Mothers/Caregivers in a Developing Setting

Objectives:
Neonatal jaundice (NNJ) is a common newborn disorder globally which is preventable and easily treatable. However, when detected late and/or poorly
managed, it is a leading cause of hospitalization, neurological complications and death in newborns. Since mother’s knowledge of newborn jaundice
is crucial to prompt recognition, intervention and prevention of morbidity and mortality associated with this condition, we sought to determine the
knowledge, perception and care seeking behaviours of NNJ among mothers/caregivers.

 

View Full Article : HERE

Go Through The Journal : http://www.enlivenarchive.org/pediatrics-and-neonatal-biology

Contact Us : pediatrics-neonatal@enlivenarchive.org

 

Angiotensin (1-7) Antagonist Diminished the Anti-Tumor Effect of Olmesartan in Tumor Cell Lines Grown In-vitro and In-vivo

Olmesartan is a selective angiotensin II type 1 receptor (AT1R) antagonist. It achieves blood pressure reduction in a dose-dependent manner through arterial vasodilation and reduced sodium retention. Secondly, olmesartan exhibits anti-angiogenic activity through inhibition of Insulin growth factor, vascular endothelial growth factor and their receptors and this effect was mediated through the Ang (1-7). The current study was to investigate the anti-tumor effect of olmesartan; first, the cytotoxic activity of olmesartan and/or Ang (1-7) antagonist on MCF-7 cell line using 3-[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay was explored. Then EAC solid tumor grown in vivo was employed to determine the impact of concurrent administration of an Ang (1–7) agonist or antagonist on the anti-tumor effect of olmesartan. In addition, the impact of concurrent administration of olmesartan on the cytotoxic activity of sorafenib in MCF-7 cell line or its anti-tumor effect in EAC solid tumor grown in vivo was investigated. It was observed that the cell viability was reduced by approximately 40% after sorafenib (250 μg/ml) treatment. On the other hand, olmesartan did not show any cytotoxic effect except when higher concentrations were used. IC50 value for sorafenib in MCF-7 was 250.9 μg/ml, while the IC50 value for olmesartan was 674.8 μg/ml. Ang (1-7) antagonist increased the IC50 value of olmesartan from 674.8 μg/ml to 722 μg/ml. The high cytotoxic concentration of olmesartan in combination with sorafenib failed to enhance the cytotoxicity more than the sorafenib itself. Sorafenib (30 mg/kg/day), olmesartan (3, 10 or 30 mg/kg/day) or their combination significantly (P<0.05) reduced tumor volume and the relative tumor volume compared to EAC-Control group. Similarly, concurrent administration of the Ang (1-7) agonist with olmesartan (30 mg/kg) significantly (P<0.05) reduced tumor volume and the relative tumor volume compared to EAC-control group or olmesartan (30 mg/kg) group. Moreover, the administration of Ang (1-7) antagonist with olmesartan reduced the anti-tumor effect of olmesartan. In conclusion, olmesartan (30 mg/kg) posses anti-tumor activity. This anti-tumor activity did not depend on the direct cytotoxic activity but might be attributed to antiangiogenic activity as proven in a previous work from our lab. The anti-tumor effect of olmesartan was, at least in part, mediated through the Ang (1-7) receptor. In addition, the present results showed that olmesartan (30 mg/kg) potentiated the anti-tumor effect of sorafenib.

 

View Full Article: HERE

Go through the Journal: http://www.enlivenarchive.org/challenges-in-cancer-detection-and-therapy

Contact Us: cancer@enlivenarchive.org

 

 

A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells

Ovarian cancer is the second most common gynecological cancer and the five-year survival rate is only about 40%. High-grade serous carcinoma is the pre-dominant histotype associated with hereditary ovarian cancer and women with inherited mutations in BRCA1 have a lifetime risk of 40-60%. BRCA1 and its isoform BRCA1a are multifunctional proteins that are the most evolutionary conserved of all the other splice variants. Our group has previously reported that BRCA1/1a proteins, unlike K109R and C61G mutants, suppress growth of ovarian cancer cells by tethering Ubc9. In this study we found wild type BRCA1/1a proteins to induce expression of caveolin-1, a tumor suppressor in BRCA1-mutant serous epithelial ovarian cancer (SEOC) cells by immunofluorescence analysis. The K109R and C61G disease associated mutant BRCA1 proteins that do not bind Ubc9 were not as efficient in up-regulation of caveolin-1 expression in SEOC cells. Additionally, immunofluorescence analysis showed BRCA1/1a proteins to induce redistribution of Caveolin-1 from cytoplasm and nucleus to the cell membrane. This is the first study demonstrating the physiological link between loss of Ubc9 binding, loss of growth suppression and loss of Caveolin-1 induction of disease-associated mutant BRCA1 proteins in SEOC cells. Decreased Caveolin-1 expression combined with elevated Ubc9 expression can in the future be used as an early biomarker for BRCA1 mutant SEOC.

 

View Full Article: HERE

Go through the Journal: http://www.enlivenarchive.org/challenges-in-cancer-detection-and-therapy

Contact Us:cancer@enlivenarchive.org

 

Study on Effect of Buqi-Tongluo-Jiedu Decoction on Protein Concentration of HIC1/SIRT1 of Pancreatic Cancer Model Mice

Objective: To observe the effect of protein concentration of HIC1/SIRT1 on pancreatic cancer model mice.

Method: 30 mice were randomly selected and divided into three groups, each group comprised 10 mice. Cancer cells were injected into model mice. Normal group and model group were given saline. The treatment group was given Buqi-Tongluo-Jiedu decoction. After 14 days, after administering euthanasia the tumor tissues were removed. To detect HIC1/SIRT1 protein concentration, the specimens of each group were examined by WB method.

View Full Article: HERE

Go through the  Journal: http://www.enlivenarchive.org/challenges-in-cancer-detection-and-therapy/

Contact Us: cancer@enlivenarchive.org